Genprex (NASDAQ : GNPX) is a clinical-stage biopharmaceutical company developing novel gene therapies to improve outcomes for cancer patients receiving promising targeted and immunotherapies, as well as to expand therapeutic benefits to a greater number of patients. The Company’s unique approach to cancer treatment is grounded in its proprietary gene therapy platform with broad application to utilize multiple tumor suppressor genes, provide multiple synergies with targeted drug treatments, and address a range of cancer indications. Genprex’s lead product candidate, OncoprexTM, has been developed on this cutting-edge platform and combines the features of gene therapy and immunotherapy to provide a multimodal approach to treating cancer.

Contact Genprex
Visit Website